마이크로바이옴 진단 시장 : 제품, 기술, 샘플, 용도, 최종 용도별 - 세계 예측(2024-2032년)

Global Microbiome Diagnostics Market size will expand at 13.4% CAGR from 2024 to 2032, fueled by advancements in sequencing technologies, such as next-generation sequencing NGS, coupled with the rising incidence of chronic diseases. These technologies are enabling detailed analysis of microbial communities for offering insights into disease mechanisms and personalized treatment strategies.

With the healthcare sector increasingly focusing on preventive and personalized medicine, microbiome diagnostics are playing a crucial role in understanding disease pathways and optimizing patient care, driving growth in both research and clinical applications. For instance, in February 2024, ALS launched the Gut Microbiome Sequencing service for providing global researchers with comprehensive, publication-ready data to gain profound insights into the human and animal gut microbiome.

The microbiome diagnostics industry is divided based on product, technology, sample, application, end-use, and region.

By technology, the shotgun metagenomics segment will secure a noteworthy CAGR through 2032, attributed to its comprehensive approach in analyzing microbial DNA directly from samples. This method offers detailed insights into microbial communities for aiding in precise disease diagnosis and therapeutic strategies. With advancements in sequencing technologies and bioinformatics, shotgun metagenomics are further enabling a deeper understanding of microbiome composition and function

In terms of sample, the microbiome diagnostics market size from the saliva samples segment will grow by 2032. By offering non-invasive collection and diverse microbial representation, saliva samples facilitate convenient and repeated testing. They also provide insights into oral and systemic health for supporting personalized medicine and wellness assessments. Rising research is also expanding the role in of oral microbiome in various diseases, including metabolic disorders and oral cancers. Moreover, saliva-based diagnostics are increasingly recognized for their efficacy and accessibility in advancing microbiome research and clinical applications.

Asia Pacific microbiome diagnostics market will record a remarkable CAGR between 2024 and 2032, propelled by the increasing healthcare expenditure and the rising awareness of personalized medicine. With expanding research initiatives and adoption of advanced diagnostic technologies, the diverse population of the region is contributing to the understanding of microbiome variations. As governments prioritize healthcare infrastructure and regulatory frameworks, Asia Pacific will emerge as a significant contributor to advancing microbiome diagnostics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Increasing prevalence of chronic diseases
  • 3.2.3 Rising demand of personalized medicine
  • 3.2.4 Growing awareness about importance of human microbiomes
  • 3.2.5 Rising funding and investments in microbiome research
  • 3.2.6 Industry pitfalls & challenges
  • 3.2.7 High cost associated with microbiome testing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Kits and reagents
• 5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 16S rRNA sequencing
• 6.3 Shotgun metagenomics
• 6.4 Metatranscriptomics
• 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Sample, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Fecal samples
• 7.3 Saliva samples
• 7.4 Skin samples
• 7.5 Other samples

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Disease diagnostic
  • 8.2.1 Gastrointestinal disorders
  • 8.2.2 Metabolic disorders
  • 8.2.3 Other disease diagnostics
• 8.3 Research applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Academic and research institutes
• 9.4 Pharmaceuticals and biotechnology companies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Becton, Dickinson, and Company
• 11.2 Biome Technologies plc
• 11.3 Genetic Analysis AS
• 11.4 Illumina, Inc.
• 11.5 Microba Life Sciences Limited
• 11.6 Micronoma, Inc.
• 11.7 OraSure Technologies, Inc.
• 11.8 Oxford Nanopore Technologies plc
• 11.9 Quantbiome, Inc.
• 11.10 ViennaLab Diagnostics GmbH